EARS Auris Medical Holding AG

Auris Medical Announces Initiation of Part B of TRAVERS Phase 2 Study with AM-125 in Vertigo

Auris Medical Announces Initiation of Part B of TRAVERS Phase 2 Study with AM-125 in Vertigo
EN
13/10/2020

Underlying

EARSAuris Medical Holding AG

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Auris Medical Holding AG

 PRESS RELEASE
Free
EARS Auris Medical H...

Auris Medical Announces Launch of New Corporate Website

Auris Medical Announces Launch of New Corporate Website Hamilton, Bermuda, July 15, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced the launch of its newly-designed corporate website . The new website features a streamlined and modern design and also reflects the Company’s recently announced strategic repositioning. “We are proud to present our projects and products as well as the science behind them through a completely red...

July 16, 2021 1 EN
 PRESS RELEASE
Free
EARS Auris Medical H...

Auris Medical Announces Publication of Data from Preclinical Studies w...

Auris Medical Announces Publication of Data from Preclinical Studies with Bentrio™ Nasal Spray in Prevention and Mitigation of SARS-CoV-2 Bentrio™ formulation well tolerated in vitro on human nasal epitheliumUp to 99% reduction of SARS-CoV-2 viral titer with prophylactic treatment vs. controlsViral titer reduced 12- or 14-fold vs. controls when treatment started 24 or 30 h post infection Hamilton, Bermuda, July 14, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and i...

July 14, 2021 1 EN
 PRESS RELEASE
Free
EARS Auris Medical H...

Auris Medical to Develop KRAS-Targeting RNA Treatment for Colorectal C...

Auris Medical to Develop KRAS-Targeting RNA Treatment for Colorectal Cancer as First Therapeutic Indication for OligoPhore™ Technology Treatment of KRAS-driven colorectal cancer selected as first therapeutic indication for OligoPhore™ platformCompany to launch development program under project code AM-401 with aim of IND submission in late 2022 Hamilton, Bermuda, July 6, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced the se...

July 6, 2021 1 EN
 PRESS RELEASE
Free
EARS Auris Medical H...

Auris Medical to Initiate Market Launch of Bentrio™ Nasal Spray in Ger...

Auris Medical to Initiate Market Launch of Bentrio™ Nasal Spray in Germany Hamilton, Bermuda, June 28, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced that its affiliate Altamira Medica Ltd. will start the market roll-out of Bentrio™, its nasal spray for protection against airborne viruses and allergens, by launching it in Germany. Bentrio™ will shortly become available through selected online pharmacies; over the coming months...

June 28, 2021 1 EN
 PRESS RELEASE
Free
EARS Auris Medical H...

Auris Medical Announces Significant Inhibition of Tumor Growth with Ol...

Auris Medical Announces Significant Inhibition of Tumor Growth with OligoPhore siRNA Targeting NF-κB in Murine Model of Adult T-Cell Leukemia / Lymphoma Treatment with OligoPhoreTM siRNA stops aggressive ATLL tumor growth to near zeroSignificant reduction in tumor size, spleen size and peripheral blood lymphocyte countsResults add to extensive body of evidence for effective OligoPhoreTM enabled delivery of nucleic acids to extrahepatic tissues Hamilton, Bermuda, June 21, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA t...

June 21, 2021 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch